Frontline chemoimmunotherapy with nivolumab and dose-adjusted EPOCH in peripheral T-cell lymphoma: a phase 1 trial

Blood Adv. 2024 Feb 13;8(3):708-711. doi: 10.1182/bloodadvances.2023011526.

Authors

Affiliations

¹ Division of Hematology, University of Colorado, Aurora, CO.
² Division of Hematology, City of Hope, Duarte, CA.
³ Division of Hematology and Oncology, Virginia Commonwealth University, Richmond, VA.
⁴ Division of Oncology, University of Colorado, Aurora, CO.
⁵ Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA.

No abstract available

Publication types

Clinical Trial, Phase I
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Lymphoma, T-Cell, Peripheral* / drug therapy
Nivolumab* / adverse effects

Substances

Nivolumab